相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma
Dachuan Huang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
Tayla B. Heavican et al.
BLOOD (2019)
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
R. D. Kim et al.
BRITISH JOURNAL OF CANCER (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma
Yonghuan Mao et al.
TRANSLATIONAL ONCOLOGY (2018)
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz et al.
LANCET ONCOLOGY (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies
Benjamin W. Teh et al.
LEUKEMIA & LYMPHOMA (2016)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Hung Huynh et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe Odejide et al.
BLOOD (2014)
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
James S. Blachly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2014)
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma
Hae Yong Yoo et al.
NATURE GENETICS (2014)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
P. L. Zinzani et al.
ANNALS OF ONCOLOGY (2010)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
